Preview

Кардиология

Расширенный поиск

Фибрилляция предсердий у больных, находящихся на диализной терапии: эпидемиология, прогноз и выбор антикоагулянтной терапии

https://doi.org/10.18087/cardio.2019.12.n733

Полный текст:

Аннотация

В обзоре представлены данные по распространенности фибрилляции предсердий (ФП) у больных, находящихся на диализной терапии. Показано, что у диализ-зависимых пациентов с неклапанной ФП прогноз крайне неблагоприятный, значительно увеличен риск смерти как за счет ишемических, так и геморрагических осложнений. Шкалы для оценки риска развития тромбоэмболических и геморрагических осложнений у больных с ФП, находящихся на программном диализе, не валидизированы. Отсутствие данных рандомизированных клинических исследований значительно затрудняет выбор антикоагулянтной терапии у больных с терминальной стадией хронической болезни почек, находящихся на диализе, перенесших трансплантацию почки. Поэтому необходимость антикоагулянтной терапии и выбор препаратов у больных данной категории должен быть сделан на основе персонализированного мультидисциплинарного подхода с учетом коморбидной патологии и предпочтений больного.

Об авторах

Н. А. Козиолова
ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е. А. Вагнера» Минздрава России
Россия
Пермь


Е. А. Полянская
ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е. А. Вагнера» Минздрава России
Россия
Пермь


А. И. Чернявина
ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е. А. Вагнера» Минздрава России
Россия
Пермь


С. В. Миронова
ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е. А. Вагнера» Минздрава России
Россия
Пермь


Список литературы

1. Poulikakos D, Hnatkova K, Skampardoni S, Green D, Kalra P, Malik M. Sudden Cardiac Death in Dialysis: Arrhythmic Mechanisms and the Value of Non-invasive Electrophysiology. Frontiers in Physiology. 2019;10:144. DOI: 10.3389/fphys.2019.00144

2. Tumlin JA, Roy-Chaudhury P, Koplan BA, Costea AI, Kher V, Williamson D et al. Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study. BMC Nephrology. 2019;20(1):80. DOI: 10.1186/s12882-019-1212-6

3. Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D et al. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney International. 2018;93(4):941–51. DOI: 10.1016/j.kint.2017.11.019

4. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The Increasing Prevalence of Atrial Fibrillation among Hemodialysis Patients. Journal of the American Society of Nephrology. 2011;22(2):349–57. DOI: 10.1681/ASN.2010050459

5. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaideligible dialysis patients. Kidney International. 2012;81(5):469–76. DOI: 10.1038/ki.2011.416

6. Tanaka A, Inaguma D, Shinjo H, Takeda A. Incidence rate of atrial fibrillation after dialysis initiation and its relationship with cardiovascular events. Acta Cardiologica. 2019;1–9. [Epub ahead of print]. DOI: 10.1080/00015385.2018.1530085

7. Sánchez Perales C, Vázquez Sánchez T, Salas Bravo D, Ortega Anguiano S, Vázquez Ruiz de Castroviejo E. Fibrilación auricular en los pacientes en hemodiálisis en Andalucía. Prevalencia, perfil clínico y manejo terapéutico. Nefrología. 2018;38(3):286–96. DOI: 10.1016/j.nefro.2017.09.003

8. Königsbrügge O, Posch F, Antlanger M, Kovarik J, KlauserBraun R, Kletzmayr J et al. Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PLOS ONE. 2017;12(1):e0169400. DOI: 10.1371/journal.pone.0169400

9. Shiao C-C, Kan W-C, Wang J-J, Lin Y-F, Chen L, Chueh E et al. Risk of Incident Non-Valvular Atrial Fibrillation after Dialysis-Requiring Acute Kidney Injury. Journal of Clinical Medicine. 2018;7(9):248. DOI: 10.3390/jcm7090248

10. Abuhasira R, Mizrakli Y, Shimony A, Novack V, Shnaider A, Haviv YS. Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis. Scientific Reports. 2018;8(1):2976. DOI: 10.1038/s41598-018-21229-9

11. Niu J, Shah MK, Perez JJ, Airy M, Navaneethan SD, Turakhia MP et al. Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD. American Journal of Kidney Diseases. 2019;73(3):324–31. DOI: 10.1053/j.ajkd.2018.09.011

12. Cho Y, Johnson DW, Badve S, Craig JC, Strippoli GFK, Wiggins KJ. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation. 2013;28(7):1899–907. DOI: 10.1093/ndt/gft050

13. Franczyk B, Gluba-Brzózka A, Bartnicki P, Rysz J. The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. International Urology and Nephrology. 2017;49(6):1071–7. DOI: 10.1007/s11255-017-1506-1

14. Hensen LCR, Delgado V, van Wijngaarden SE, Leung M, de Bie MK, Buiten MS et al. Echocardiographic associates of atrial fibrillation in end-stage renal disease. Nephrology Dialysis Transplantation. 2017;32(8):1409–14. DOI: 10.1093/ndt/gfw352

15. Martin RIR, Babaei MS, Choy M-K, Owens WA, Chico TJA, Keenan D et al. Genetic variants associated with risk of atrial fibrillation regulate expression of PITX2, CAV1, MYOZ1, C9orf3 and FANCC. Journal of Molecular and Cellular Cardiology. 2015;85:207–14. DOI: 10.1016/j.yjmcc.2015.06.005

16. Saracyn M, Kisiel B, Bachta A, Franaszczyk M, Brodowska-Kania D, Żmudzki W et al. Value of multilocus genetic risk score for atrial fibrillation in end-stage kidney disease patients in a Polish population. Scientific Reports. 2018;8(1):9284. DOI: 10.1038/s41598-018-27382-5

17. Turakhia MP, Blankestijn PJ, Carrero J-J, Clase CM, Deo R, Herzog CA et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal. 2018;39(24):2314–25. DOI: 10.1093/eurheartj/ehy060

18. Cheng X, Nayyar S, Wang M, Li X, Sun Y, Huang W et al. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data. Nephrology Dialysis Transplantation. 2013;28(3):724–32. DOI: 10.1093/ndt/gfs326

19. Chao T-F, Liu C-J, Wang K-L, Lin Y-J, Chang S-L, Lo L-W et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm. 2014;11(10):1752–9. DOI: 10.1016/j.hrthm.2014.06.021

20. Mitsuma W, Matsubara T, Hatada K, Imai S, Tamura M, Tsubata Y et al. Atrial Fibrillation Had Less Impact on the Risk of Ischemic Stroke in Non-anticoagulated Patients Undergoing Hemodialysis: Insight from the RAKUEN study. Internal Medicine. 2018;57(16):2295–300. DOI: 10.2169/internalmedicine.0021-17

21. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of Stroke among Chronic Hemodialysis Patients with Nonrheumatic Atrial Fibrillation. American Journal of Nephrology. 2001;21(1):35–9. DOI: 10.1159/000046216

22. Chan P-H, Huang D, Yip P-S, Hai J, Tse H-F, Chan T-M et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace. 2016;18(5):665–71. DOI: 10.1093/europace/euv289

23. Molnar AO, Sood MM. Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation. Seminars in Dialysis. 2018;31(1):37–47. DOI: 10.1111/sdi.12637

24. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127(2):224–32. DOI: 10.1161/CIRCULATIONAHA.112.107128

25. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N et al. A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. Journal of the American Heart Association. 2013;2(3):e000250. DOI: 10.1161/JAHA.113.000250

26. Garlo KG, Steele DJR, Nigwekar SU, Chan KE. Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. 2019;14(1):125–36. DOI: 10.2215/CJN.06430518

27. Keskar V, Sood MM. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. Clinical Journal of the American Society of Nephrology. 2016;11(11):2085–92. DOI: 10.2215/CJN.03200316

28. Wong CX, Odutayo A, Emdin CA, Kinnear NJ, Sun MT. MetaAnalysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis. The American Journal of Cardiology. 2016;117(12):1934–41. DOI: 10.1016/j.amjcard.2016.03.042

29. McCullough PA, Ball T, Cox KM, Assar MD. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. Clinical Journal of the American Society of Nephrology. 2016;11(11):2079–84. DOI: 10.2215/CJN.02680316

30. Liu G, Long M, Hu X, Hu C-H, Liao X-X, Du Z-M et al. Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies. Medicine. 2015;94(50):e2233. DOI: 10.1097/MD.0000000000002233

31. Tan J, Liu S, Segal JB, Alexander GC, McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrology. 2016;17(1):157. DOI: 10.1186/s12882-016-0368-6

32. Nochaiwong S, Ruengorn C, Awiphan R, Dandecha P, Noppakun K, Phrommintikul A. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000441. DOI: 10.1136/openhrt-2016-000441

33. Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT et al. Warfarin and the risk of stroke and bleeding in patients with arial fibrillation receiving dialysis: a systematic review and meta-analysis. The Canadian Journal of Cardiology. 2017;33(6):737–46. DOI: 10.1016/j.cjca.2017.02.004

34. Yoon C-Y, Noh J, Jhee JH, Chang TI, Kang EW, Kee YK et al. Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study. Stroke. 2017;48(9):2472–9. DOI: 10.1161/STROKEAHA.117.017114

35. Voskamp PWM, Rookmaaker MB, Verhaar MC, Dekker FW, Ocak G. Vitamin K antagonist use and mortality in dialysis patients. Nephrology Dialysis Transplantation. 2018;33(1):170–6. DOI: 10.1093/ndt/gfx199

36. Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. American Heart Journal. 2017;184:37–46. DOI: 10.1016/j.ahj.2016.09.016

37. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. American Journal of Kidney Diseases. 2015;66(4):677–88. DOI: 10.1053/j.ajkd.2015.05.019

38. Kai B, Bogorad Y, Nguyen L-AN, Yang S-J, Chen W, Spencer HT et al. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm. 2017;14(5):645–51. DOI: 10.1016/j.hrthm.2017.01.047

39. Tan J, Bae S, Segal JB, Zhu J, Alexander GC, Segev DL et al. Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation: Warfarin risks in older adults on dialysis. Nephrology. 2019;24(2):234–44. DOI: 10.1111/nep.13207

40. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330–93. DOI: 10.1093/eurheartj/ehy136

41. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Heart Rhythm. 2019;16(8):e66–93. DOI: 10.1016/j.hrthm.2019.01.024

42. Brancaccio D, Neri L, Bellocchio F, Barbieri C, Amato C, Mari F et al. Atrial Fibrillation in Dialysis Patients: Time to Abandon Warfarin? The International Journal of Artificial Organs. 2016;39(3):99–105. DOI: 10.5301/ijao.5000487

43. Bansal VK, Herzog CA, Sarnak MJ, Choi MJ, Mehta R, Jaar BG et al. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. American Journal of Kidney Diseases. 2017;70(6):859–68. DOI: 10.1053/j.ajkd.2017.08.003

44. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972–9. DOI: 10.1161/CIRCULATIONAHA.114.014113

45. Awesat J, Sagy I, Haviv YS, Rabinovich A, Jotkowitz A, Shleyfer E et al. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review. Thrombosis Research. 2018;169:120–2. DOI: 10.1016/j.thromres.2018.07.019

46. Chan KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. Journal of the American College of Cardiology. 2016;67(24):2888–99. DOI: 10.1016/j.jacc.2016.02.082

47. Mlodawska E, Lopatowska P, Malyszko J, Banach M, Sobkowicz B, Covic A et al. Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants? International Urology and Nephrology. 2018;50(9):1633–42. DOI: 10.1007/s11255-018-1877-y

48. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138(15):1519–29. DOI: 10.1161/CIRCULATIONAHA.118.035418

49. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing and Clinical Electrophysiology. 2018;41(6):627–34. DOI: 10.1111/pace.13331

50. Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke A-K et al. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. The American Journal of Medicine. 2019;pii: S0002-9343(19)30355-9. [Epub ahead of print]. DOI: 10.1016/j.amjmed.2019.04.013

51. Collister D, Healey JS, Conen D, Brimble KS, Rigatto C, Harel Z et al. Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey. Canadian Journal of Kidney Health and Disease. 2019;6:205435811882194. DOI: 10.1177/2054358118821945

52. Genovesi S, Slaviero G, Porcu L, Casu G, Bertoli S, Sagone A et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. International Journal of Cardiology. 2018;262:38–42. DOI: 10.1016/j.ijcard.2018.03.083

53. Di Lullo L, Tripepi G, Ronco C, De Pascalis A, Barbera V, Granata A et al. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. Journal of Nephrology. 2018;31(5):751–6. DOI: 10.1007/s40620-018-0501-7

54. Di Lullo L, Tripepi G, Ronco C, D’Arrigo G, Barbera V, Russo D et al. Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. International Journal of Cardiology. 2019;278:243–9. DOI: 10.1016/j.ijcard.2018.11.119

55. FDA. Drug Approval Package. Eliquis (apixaban) 2.5 and 5 mg Tablets. [Internet] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm

56. FDA. Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439. [Internet] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202439toc.cfm

57. FDA. Drug Approval Package: PRADAXA (dabigatran etexilate mesylate) NDA #022512. [Internet] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000TOC.cfm

58. Kooiman J, van der Hulle T, Maas H, Wiebe S, Formella S, Clemens A et al. Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease. Journal of the American College of Cardiology. 2016;67(20):2442–4. DOI: 10.1016/j.jacc.2016.03.516

59. Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM et al. Pharmacokinetics, Pharmacodynamics, and Safety of SingleDose Rivaroxaban in Chronic Hemodialysis. American Journal of Nephrology. 2016;43(4):229–36. DOI: 10.1159/000445328

60. De Vriese AS, Caluwé R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B et al. Dose-Finding Study of Rivaroxaban in Hemodialysis Patients. American Journal of Kidney Diseases. 2015;66(1):91–8. DOI: 10.1053/j.ajkd.2015.01.022

61. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. The Journal of Clinical Pharmacology. 2016;56(5):628–36. DOI: 10.1002/jcph.628

62. US National Library of Medicine. Oral Anticoagulation in Haemodialysis Patients. [Internet] Available at: https://clinicaltrials.gov/ct2/show/NCT02886962

63. US National Library of Medicine. Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD). [Internet] Available at: https://clinicaltrials.gov/ct2/show/NCT02933697

64. Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open. 2018;8(9):e022690. DOI: 10.1136/bmjopen-2018-022690

65. US National Library of Medicine. Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation. [Internet] Available at: https://clinicaltrials.gov/ct2/show/NCT02942407

66. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. Journal of the American Society of Nephrology. 2017;28(7):2241–8. DOI: 10.1681/ASN.2016090980

67. Galloway PAG, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK et al. Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease. Nephron. 2015;129(3):197–201. DOI: 10.1159/000371449

68. Han KH, O’Neill WC. Increased Peripheral Arterial Calcification in Patients Receiving Warfarin. Journal of the American Heart Association. 2016;5(1):e002665. DOI: 10.1161/JAHA.115.002665

69. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circulation Journal. 2015;79(7):1486–95. DOI: 10.1253/circj.CJ-14-0942

70. Deal EN, Pope H, Ross W. Apixaban Use Among Patients With Severe Renal Impairment. Annals of Pharmacotherapy. 2014;48(12):1667. DOI: 10.1177/1060028014554446

71. Lehr T, Haertter S, Liesenfeld K-H, Staab A, Clemens A, Reilly PA et al. Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. The Journal of Clinical Pharmacology. 2012;52(9):1373–8. DOI: 10.1177/0091270011417716

72. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrology Dialysis Transplantation. 2012;27(10):3816–22. DOI: 10.1093/ndt/gfs416


Для цитирования:


Козиолова Н.А., Полянская Е.А., Чернявина А.И., Миронова С.В. Фибрилляция предсердий у больных, находящихся на диализной терапии: эпидемиология, прогноз и выбор антикоагулянтной терапии. Кардиология. 2019;59(12):72-83. https://doi.org/10.18087/cardio.2019.12.n733

For citation:


Koziolova N.A., Polyanskaya E.A., Chernyavina A.I., Mironova S.V. Atrial Fibrillation in Patients on Dialysis Therapy: Epidemiology, Prognosis and Choice of Anticoagulant Therapy. Kardiologiia. 2019;59(12):72-83. (In Russ.) https://doi.org/10.18087/cardio.2019.12.n733

Просмотров: 676


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)